Asthma and COVID-19: a systematic review
Allergy, Asthma & Clinical Immunology volume 17, Article number: 5 (2021)
Severe coronavirus disease-19 (COVID-19) presents with progressive dyspnea, which results from acute lung inflammatory edema leading to hypoxia. As with other infectious diseases that affect the respiratory tract, asthma has been cited as a potential risk factor for severe COVID-19. However, conflicting results have been published over the last few months and the putative association between these two diseases is still unproven.
Here, we systematically reviewed all reports on COVID-19 published since its emergence in December 2019 to June 30, 2020, looking into the description of asthma as a premorbid condition, which could indicate its potential involvement in disease progression.
We found 372 articles describing the underlying diseases of 161,271 patients diagnosed with COVID-19. Asthma was reported as a premorbid condition in only 2623 patients accounting for 1.6% of all patients.
As the global prevalence of asthma is 4.4%, we conclude that either asthma is not a premorbid condition that contributes to the development of COVID-19 or clinicians and researchers are not accurately describing the premorbidities in COVID-19 patients.
COVID-19 was first reported in December, 2019 in Wuhan, China, and rapidly spread across the globe . It has affected more than 54 million people and has led to the death of over 1.3 million as of November 16, 2020 (www.who.org). Severely affected patients present fever, dry cough, dyspnea, and fatigue, which are commonly associated with the development of pneumonia and acute respiratory distress syndrome (ARDS) . Advanced age, ischemic and congestive heart disease, hypertension, diabetes, and chronic obstructive pulmonary disease (COPD) are the most important independent predictors of death [2, 3]. As with other infectious diseases affecting the lungs, asthma has been cited as a potential risk factor for severe COVID-19 [4,5,6,7,8]. This association could be putatively explained on the basis of an abnormal immune response occurring in the context of the allergic condition and an abnormal respiratory function [9, 10]. However, no previous study has addressed this question looking into all studies that described the clinical features of COVID-19.
Here, we systematically reviewed all studies published on COVID-19 since its emergence in December 2019 to June 30, 2020, looking into the description of asthma as a premorbid condition and its putative association with severe progression of the disease. We show that out of 161,271 patients diagnosed with COVID-19 and having their premorbid conditions described, only 1.6% were reported as previously diagnosed with asthma.
This is a systematic review of the diagnosis of asthma as a premorbid condition in patients with COVID-19. The report was organized according to the Preferred Reporting Items for Systematic Reviews . Two authors, NFM and CPJ, independently identified cross-sectional and longitudinal studies published before June 30, 2020, that reported on the prevalence of asthma as a premorbid condition of severe COVID-19 by systematically searching PubMed-NCBI, Google Scholar, Scopus and Web of Science databases. As previously reported, PubMed-NCBI alone covers more than 90% of MEDLINE providing a widely accessible biomedical resource . For database searches, language of the article was restricted to English. Search terms included the following: COVID-19 (COVID, COVID 19) or nCov or novel coronavirus or Sars-Cov-2 in the title and clinical characteristics or asthma anywhere in the text. Three authors, EM, EPA, and LAV, resolved eventual discrepancies by discussion and adjudication.
We found 1069 articles that met the initial inclusion search criteria. All articles were assessed by authors and 598 were excluded (Additional file 1: Table 1) due to one or more of the following criteria: editorials; metanalyses; systematic reviews; commentaries; letters to the Editor; no description of patient’s clinical characteristics or premorbid conditions; duplicated articles and main text in a language other than English. We found 99 studies duplicated, which were also excluded accordingly, allowing us to analyze only in one of the both versions. The remaining 372 articles were included in the study. Additional file 1: Table 2 depicts the details of all articles analyzed.
Two authors, NFM and CPJ, independently extracted the following data from each article using a standardized form: study design; number of patients with COVID-19; mention of any respiratory disease; number of patients with any respiratory disease; mention of asthma; number of patients with the previous diagnosis of asthma. The entire body of the articles was presented descriptively.
Figure 1 is a schematic representation of search, inclusion and exclusion of articles. Our search criteria resulted in the identification of 1069 articles that were pre-selected for detailed analysis resulting in the exclusion of 598 articles (Additional file 1: Table 1) due to one or more of the following reasons: editorials; metanalyses; systematic reviews; commentaries; letters to the Editor; no description of patient’s clinical characteristics or premorbid conditions; and main text in a language other than English. The remaining 372 articles (Additional file 1: Table 2) described the clinical aspects of 161,271 COVID-19 patients. Two hundred and one studies mentioned the existence of other respiratory premorbidities except for asthma. Althought asthma was mentioned as a underlying disease in 67 studies, only 52 articles have described the exact number of the COVID-19 patients with asthma (Table 1). The other 15 studies presented asthma together with other respiratory diseases, making it impossible to identify the number of COVID-19 asthmatic patients. There was a total of 40,948 COVID-19 patients included in the studies mentioning asthma, of which 8439 were previously diagnosed with asthma. In most of the studies describing other respiratory illnesses, COPD was the leading diagnosis. The United States was the country with the largest number of studies describing asthma, followed by China, France, Spain and the United Kingdom (Fig. 2a).
Thus, according to current COVID-19 clinical records, 6.4% of patients included in articles describing the clinical characteristics of COVID-19 patients and citing asthma were previously diagnosed with asthma (Fig. 2b). If all studies providing any clinical description of COVID-19 comorbidities are taken into consideration, asthma was present in only 1.6% of patients (Fig. 2c).
Asthma is a highly prevalent, chronic, non-communicable disease that affects up to 4.4% of the world’s population (http://www.globalasthmareport.org; https://www.who.int/news-room/q-a-detail/asthma). Its recurrent nature leads to frequent hospitalizations and high mortality, ranging from 2 to 4/100,000 . Respiratory viruses can trigger asthma exacerbations, which can increase the severity of the infectious condition . In the past, coronaviruses have been implicated as triggers of asthma exacerbations [15, 16]; this is also true for influenza virus . However, as for the new coronavirus, SARS-CoV-2, there is still controversy regarding the putative role of asthma as a premorbid that could worsen disease progression [7, 8, 18].
Here, we evaluated all studies on COVID-19 published since its emergence up to June 30, 2020. We showed that asthma was described as a premorbid condition in only 1.6% of all patients. These numbers are far less than expected considering the prevalence of asthma in the world (http://www.globalasthmareport.org; https://www.who.int/news-room/q-a-detail/asthma) and could suggest that having asthma as a premorbid condition either represents no risk for COVID-19 or could be a protective factor against the development of the disease. However, there are some aspects that should be considered as potentially impactful for the findings herein reported. First, the prevalence of asthma varies across the globe, ranging from 21% in Australia to less than 2% in China, Kazakhstan and Vietnam . Likewise, the most common risk factors for COVID-19, obesity, diabetes and hypertension, have distinct prevalences in different countries (www.who.org). Thus, the geographical origin of the studies could have influenced the results. However, as the studies included in this systematic review were mostly originated from countries presenting a wide range of prevalences for both asthma and the main comorbidities for COVID-19, we believe this factor plays a minor role in the reported findings.
Another aspect that could explain our results is that asthma treatment with inhaled corticosteroids allied to improved therapeutic and prophylactic adhesion has increased over the years, resulting in the reduction of respiratory distress episodes and allergy associated immunological imbalance [20,21,22,23]. Moreover, allergy and asthma international associations were efficient to rapidly produce and release COVID-19 guidelines that provided advice for health professionals involved in the care of asthma patients, as well as for reaching the general public [24,25,26,27]. These actions could have beneficially impacted on the control of asthma and also influenced patients to follow social isolation procedures; thus, mitigating the risk of contracting COVID-19.
It has been suggested that the particular inflammatory environment in the bronchioalveolar system of asthma patients could lead to a reduced expression of SARS-CoV-2 receptor, angiotensin converting enzyme 2 (ACE2), rendering asthma patients protected from the infection [28,29,30]. This could be due to the fact that interleukin-13 (IL-13), a cytokine involved in eosinophil recruitment to the bronchial epithelia , is capable of reducing ACE2 expression in bronchial ex-vivo human samples . In line with these findings, it has been reported that progressive increase in blood eosinophil counts is related to COVID-19 recovery. Thus, if proven correct, these data could suggest that only patients with allergic asthma are protected from COVID-19, as recently suggested [32, 33]. However, currently available data provides no sufficient detail regarding asthma etiological classification and further studies would be required in order to provide advance in this issue.
The main weaknesses of this systematic review rely on the facts that we included publications covering the initial 6 months of pandemics and as new data is published on a daily basis, some changes in the frequency of asthma could appear; moreover, readers should keep in mind that some reports show that in certain pocket populations, asthma could be an important comorbidity for COVID-19 . The reasons for these apparent discrepancies should be a focus of further studies.
Thus, as for the data analyzed in this systematic review, asthma does not seem to be an important premorbid condition in COVID-19 patients; or, conversely, it could be a protective factor, as previously proposed . The findings herein reported could be an epidemiological truth that should be further explored in mechanistic studies or could be due to the fact that researchers are not properly investigating and describing the premorbidities in COVID-19 patients. Whatever the reasons, the medical community should be aware of the implications of missing the diagnosis of a potentially severe respiratory disease such as asthma that could worsen the prognosis of COVID-19 patients.
Availability of data and materials
Data are available upon request.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:e102.
Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol Pract. 2020;8:1477.e5-1488.e5.
Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe outcomes? Allergy. 2020;75:1543–5.
Hegde S. Does asthma make COVID-19 worse? Nat Rev Immunol. 2020;20:352.
Caminati M, Lombardi C, Micheletto C, Roca E, Bigni B, Furci F, et al. Asthmatic patients in COVID-19 outbreak: few cases despite many cases. J Allergy Clin Immunol. 2020;146(3):541–2.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–9.
Ritchie AI, Jackson DJ, Edwards MR, Johnston SL. Airway epithelial orchestration of innate immune function in response to virus infection. A focus on asthma. Ann Am Thorac Soc. 2016;13 Suppl 1:S55-63.
Lambrecht BN, Hammad H. Lung dendritic cells in respiratory viral infection and asthma: from protection to immunopathology. Annu Rev Immunol. 2012;30:243–70.
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.
Williamson PO, Minter CIJ. Exploring PubMed as a reliable resource for scholarly communications services. J Med Libr Assoc. 2019;107(1):16–29.
Pennington E, Yaqoob ZJ, Al-Kindi SG, Zein J. Trends in asthma mortality in the United States: 1999 to 2015. Am J Respir Crit Care Med. 2019;199(12):1575–7.
Zheng XY, Xu YJ, Guan WJ, Lin LF. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol. 2018;163(4):845–53.
McIntosh K, Ellis EF, Hoffman LS, Lybass TG, Eller JJ, Fulginiti VA. The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children. J Pediatr. 1973;82(4):578–90.
Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ. 1993;307(6910):982–6.
Sposato B, Croci L, Canneti E, Di Tomassi M, Migliorini MG, Ricci A, et al. Influenza A H1N1 and severe asthma exacerbation. Eur Rev Med Pharmacol Sci. 2010;14(5):487–90.
Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma protective against COVID-19? Allergy. 2020. https://doi.org/10.1111/all.14426.
To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.
Riley IL, Jackson B, Crabtree D, Riebl S, Que LG, Pleasants R, et al. A scoping review of international barriers to asthma medication adherence mapped to the theoretical domains framework. J Allergy Clin Immunol Pract. 2020. https://doi.org/10.1016/j.jaip.2020.08.021.
Jeminiwa R, Hohmann L, Qian J, Garza K, Hansen R, Fox BI. Impact of eHealth on medication adherence among patients with asthma: a systematic review and meta-analysis. Respir Med. 2019;149:59–68.
Gagne M, Boulet LP, Perez N, Moisan J. Adherence stages measured by patient-reported outcome instruments in adults with asthma: a scoping review. J Asthma. 2020;57(2):179–87.
Harrison T, Pavord ID, Chalmers JD, Whelan G, Fageras M, Rutgersson A, et al. Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design. ERJ Open Res. 2020;6:00333–2019.
Pfaar O, Klimek L, Jutel M, Akdis CA, Bousquet J, Breiteneder H, et al. COVID-19 pandemic: practical considerations on the organization of an allergy clinic—an EAACI/ARIA position paper. Allergy. 2020. https://doi.org/10.1111/all.14453.
Licskai C, Yang CL, Ducharme FM, Radhakrishnan D, Podgers D, Ramsey C, et al. Key highlights from the Canadian thoracic society position statement on the optimization of asthma management during the coronavirus disease 2019 pandemic. Chest. 2020;158(4):1335–7.
Ish P, Malhotra N, Gupta NGINA. what’s new and why? J Asthma. 2020;2020:1–5.
Klimek L, Jutel M, Bousquet J, Agache I, Akdis C, Hox V, et al. Management of patients with chronic rhinosinusitis during the COVID-19 pandemic—an EAACI position paper. Allergy. 2020. https://doi.org/10.1111/all.14629.
Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020;146(1):80e8-88 e8.
Hernandez-Cedillo A, Garcia-Valdivieso MG, Hernandez-Arteaga AC, Patino-Marin N, Vertiz-Hernandez AA, Jose-Yacaman M, et al. Determination of sialic acid levels by using surface-enhanced Raman spectroscopy in periodontitis and gingivitis. Oral Dis. 2019;25(6):1627–33.
Sidarta-Oliveira D, Jara CP, Ferruzzi AJ, Skaf MS, Velander WH, Araujo EP, et al. SARS-CoV-2 receptor is co-expressed with elements of the kinin-kallikrein, renin-angiotensin and coagulation systems in alveolar cells. Sci Rep. 2020;10(1):19522.
Kumar RK, Herbert C, Yang M, Koskinen AM, McKenzie AN, Foster PS. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy. 2002;32(7):1104–11.
Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You S, et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol. 2020;146(4):790–8.
Keswani A, Dhana K, Rosenthal JA, Moore D, Mahdavinia M. Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020;125(4):479–81.
Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–64.
We thank our grant providers.
NFM was supported by The São Paulo Research Foundation (grant: 2016/17810-3), and CPJ was supported by Coordination for the Improvement of Higher Education Personnel (CAPES) grant: 1744875 and 88882.434715/2019-01. EM, LAV and EPA are supported by grants from São Paulo Research Foundation (grants: 2013/07607-8 and 2020/) and Brazilian National Council of Scientific and Technological Development (CNPq).
Ethics approval and consent to participate
The study does not require ethical approval because the systematic review is based on published research and the original data are anonymous.
Consent for publication
Authors are the sole responsible for the publication of this study.
Authors have no competing interests to declare.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mendes, N.F., Jara, C.P., Mansour, E. et al. Asthma and COVID-19: a systematic review. Allergy Asthma Clin Immunol 17, 5 (2021). https://doi.org/10.1186/s13223-020-00509-y